Atopic dermatitis (eczema) is a long‑lasting skin condition that causes itchy, red, and inflamed patches. The study examines a new skin ointment that contains iodine and is identified by the code name DLQ03. Participants will receive either the DLQ03 ointment or a placebo (an inactive substance) applied to a small, controlled skin wound. The purpose of the study is to assess safety and local tolerability of the test product in people with mild to moderate atopic dermatitis who have Staphylococcus aureus on their skin.

In this early‑stage trial, volunteers are randomly placed into one of the two groups, and the staff who evaluate the results do not know which treatment each person received (blind assessment). Over several weeks, participants come to the clinic for visits where the ointment is applied, basic checks such as pulse and blood pressure are taken, and simple lab tests are performed to look for any side effects. The wound area is inspected regularly for irritation, and overall health is monitored throughout the study period.